⌕
Integra Lifesciences Holdings · IART · Nasdaq
Tenet 41 · Weak
Compare
$13.98−2.92%At closeTenet 41 · Weak
$13.98−0.42 (−2.92%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD

Integra Lifesciences Holdings (IART) Income Statement

Is this a real, growing, cash-generative business, or a story propped up by accounting?

Sources Company filings FilingsHow we compute thisNot investment advice
Business engineChoppy: revenue compounds ~1.5%/yr (FY21→FY25), net margin −31.6%. Worth your attention in FY25: Returns vs FCF (n/m). Visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)▲1.5%
1,635.2
FY21→FY25CAGR +1.5%/yr
Net income ($M)▼7337.7%
−516.5
one-off year: see footnoteCAGR —
Free cash flow ($M)—
−31.1
FY21→FY25CAGR —
Diluted EPS▼7388.9%
−6.74
buyback-liftedCAGR —
What the receipts whisper · what a headline number hides
Share count
−10.3%

85.5mn → 76.7mn diluted shares since FY21. Part of EPS growth is the shrinking denominator. Watch net income too.

Capex
$81.4M

−22.0% YoY in FY25 · 5.0% of revenue.

Returns vs FCF
n/m

$0.2M returned vs $−31.1M of FCF in FY25. Free cash flow was negative, so returns were funded from the balance sheet rather than from cash generation.

What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)1635.2Revenue−803.6COGS831.6Gross profit−99.0R&D−699.7SG&A−493.4Op income−23.1Tax & other−516.5Net income

-32¢ of every revenue dollar becomes profit. The biggest cost lever is operating expenses.

Margin trend · direction beats level Gross Operating Net
705335180%sector median net margin ~4%FY21FY25

Over this window: gross 61.2% → 50.9%. Net margin -31.6% is below the sector median.

The receipt · income statement · FY21–FY25 USD millions except per-share & ratios · hover a line for its definition
USD millions except per-share & ratios
Line itemTTM †FY25FY24FY23FY22FY21YoYCAGR 21→25
Revenue & profitability
Revenue
1,656.81,635.21,610.51,541.61,557.71,542.4▲1.5%+1.5%
Cost of revenue
789.3803.6728.5656.8587.4597.8▲10.3%+7.7%
Gross profit
867.5831.6882.1884.7970.3944.6▼5.7%−3.1%
Research & development
94.499.0115.4104.2101.293.1▼14.2%+1.6%
Selling, general & admin
685.2699.7717.0656.6616.3637.4▼2.4%+2.4%
Total operating expenses
794.81,325.0853.6773.2731.4747.4▲55.2%+15.4%
Operating incomefeeds ROC rank
72.7−493.428.4111.5238.9197.2——
Other income, net
−50.4−70.1−46.6−30.5−25.017.4——
Pretax income
22.3−563.5−18.281.1213.9214.7▼2989.9%—
Income tax
9.3−47.0−11.313.333.345.6▼316.4%—
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings
13.0−516.5−6.967.7180.6169.1▼7337.7%—
Per share
Diluted EPSbuyback-sensitive
0.16−6.74−0.090.842.161.98▼7388.9%—
Diluted shares (mn)
78.5876.6777.0180.3483.5285.48▼0.4%−2.7%
Margins
Gross margin30th pct in Healthcare
52.4%50.9%54.8%57.4%62.3%61.2%▼3.9pp−10.4pp
Operating margin
4.4%−30.2%1.8%7.2%15.3%12.8%▼31.9pp−43.0pp
Net margin41st pct in Healthcare
0.8%−31.6%−0.4%4.4%11.6%11.0%▼31.2pp−42.5pp
† TTM = trailing four quarters through 2026-09-30.FY24 effective tax rate was 62% vs a 16% norm for this window, likely a one-time item; see the filing.FY25 effective tax rate was 8% vs a 16% norm for this window, likely a one-time item; see the filing.
FY14 – FY20 · 7 more years
Unlock the full history →
5 more years of statements and CSV export are on Premium, and 7 more on Ultimate.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
Annual report filed 2026-02-26 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.

What was Integra Lifesciences Holdings' revenue last fiscal year?

Integra Lifesciences Holdings reported revenue of $1,635.2M in fiscal 2025, up 1.5% from fiscal 2024.

What was Integra Lifesciences Holdings' net income?

Integra Lifesciences Holdings reported net income of −$516.5M in fiscal 2025, a net margin of −31.6%.

Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.